On your radar > Consolidation

Email this page News by email Send a press-release

Consolidation

The pharmaceutical industry seems besieged on all sides by declining R&D productivity, expiring patents and relentless downward pricing pressure. One effect of this onslaught has been an upsurge in the level of consolidation as industry players attempt to cut costs, expand research pipelines and lengthen geographic reach.

Contract sales sector “shrunk” in 2011, PDI CEO says

21-May-2012 - The CEO of PDI said the contract sales market has “shrunk” over the past few quarters as the flow of business awards has dried up.

FDA oversight driving closures of CMOs; Interphex speaker

09-May-2012 - Increased oversight by the FDA is causing some US-based CMOs to shut down, a speaker at Interphex said.

Charles River CEO downplays interest in asset transfer deals

07-May-2012 - The CEO of Charles River said asset transfer strategic deals make little “rational sense” to clients or CROs.

Exclusive interview

Once a friend now an enemy: Over zealous EU regulators could hamper the CMO market, says analyst

25-Apr-2012 - The European CMO industry could be blocked by over complex layers of regulation, says Frost & Sullivan analyst Aiswariya Chidambaram.

Regulatory changes: the experts give us their thoughts at DIA Euromeeting

05-Apr-2012 - Regulatory reform was the name of the game at this year’s DIA Euromeeting in Denmark.

INC & inVentiv must integrate buys quickly to compete; S&P

03-Apr-2012 - INC Research and inVentiv Health must “quickly and effectively” integrate acquisitions to compete with other CROs, S&P said.

Sigma-Aldrich plans targeted models to expand service biz

03-Apr-2012 - Sigma-Aldrich plans to grow its new biologics toxicology services unit by creating targeted cell lines and animal models.

'Regulators: Get to the point', say experts at DIA Euromeeting

29-Mar-2012 - “Less bureaucracy and more research” was the Danish Minister of science and innovation’s message to regulators at this week's DIA Euromeeting.

Cetero eyes fast sale to private equity as FDA agreement nears

29-Mar-2012 - Cetero says it could have new private equity owners in 90 days and an agreed path forward with the FDA in weeks.

SEC filing sparks speculation PE firm plans Medidata takeover

19-Mar-2012 - A SEC filing has created speculation that Medidata is the target of a private equity takeover attempt by Vista Equity Partners.

European CMO market will double in just 6 years, says Frost & Sullivan

15-Mar-2012 - The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.

Patheon posts $21m dip thanks to loss of major manufacturing deal

13-Mar-2012 - Patheon took a $20.9m (€15.9m) Q1 hit in operating costs thanks to the loss of a major manufacturing supply agreement.

Private equity to buy SeraCare

14-Feb-2012 - SeraCare Life Sciences has accepted an $82m offer from a US private equity firm six months after it began searching for a buyer.

Covance looking to win biz from distracted competitors; analyst

07-Feb-2012 - Covance is investing to win business from “distracted competitors” that have been part of mergers and buyouts, an analyst claims.

Takeovers & tox top agendas as preclinical CROs’ results near

24-Jan-2012 - Preclinical CROs begin reporting full year results this week, with talk of takeovers and toxicology high on agendas.

Outsourcing still a gamble that needs strategic vision to succeed, says study

24-Jan-2012 - Outsourcing is a gamble for the industry that needs a closer collaborative approach if pharma firms want a successful performance, according to new research.

Polytherics buys Warwick Effect Polymers for biodrug modification tech

23-Jan-2012 - UK-based Polytherics has acquired Warwick Effect Polymers (WEP) to expand biologic drug modification offering.

Charles River talks up unity, ‘no comments’ takeover reports

12-Jan-2012 - Charles River’s CEO has reiterated the importance of integrating its research models and preclinical units but refused to discuss takeover reports.

CRO consolidation to slow in 2012, Icon CEO says

11-Jan-2012 - Major CRO consolidation will slow down in 2012 after the big wave of deals last year, the CEO of Icon said.

Charles River considering sale, media report claims

10-Jan-2012 - Charles River is reportedly considering selling the business, with private equity and rival companies believed to be possible buyers.

Toray takes stake in Japanese CMO to boost life sciences biz

09-Jan-2012 - Toray Industries has acquired a stake in a Japanese CMO and ingredient supplier as part of its push into life sciences.

ValiRx expands into services with biomarker business buy

05-Jan-2012 - UK-based biotech ValiRx has acquired a biomarkers business from Finnish preclinical CRO Pharmatest Services.

Charles River hunts for deals to serve strategic discovery clients

15-Dec-2011 - Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.

News in brief

Schulman Associates buys Florida IRB

06-Dec-2011 - Cincinnati, US-based Schulman Associates Institutional Review Board (IRB) has bought Florida counterpart Independent Investigational Review Board (IIR) to broaden its offering for Pharmas and CROs.